Studies tumor changes in glioblastoma that has returned after treatment
Compares returning brain tumors with first tumors in adults to find markers.
Key facts
- Who runs it
- University Hospital, Bordeaux
- Where
- Bordeaux, FranceSee the site
- Trial code
- Registry title
- Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 5 Apr 2024
- Planned end
- Apr 2026
- Type of study
- Observational
- Treatments tested
- Relapsed glioblastoma
- Record updated
- 30 July 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study looks at people over 18 who had surgery for both a first and a returned glioblastoma at the CHU de Bordeaux between 2005 and 2023.
- Age
- Over 18 years
- Sex
- All sexes
- Disease stage
- Glioblastoma that came back after the first tumor; surgery for both the first and the recurrent tumor.
- Earlier treatment
- Surgery for the first and the recurrent glioblastoma at the CHU de Bordeaux between 2005 and 2023. Systemic therapy for a tumor that is not glioblastoma is not allowed.
Main reasons for not taking part
- Received systemic therapy for a tumor that is not glioblastoma
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- age > 18 years
- surgery for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux
Who cannot take part
- systemic therapy received for non-glioblastoma tumor
Where in France
- CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie MédicaleBordeaux, FranceContact: Mathieu LARROQUETTETaking people
About the trial
What the trial wants to find out
Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol). The aim of this study is to better characterize transcriptomic, proteomic and metabolic changes in relapsed glioblastoma compared to the initial tumor, in order to identify new prognostic markers and potential new therapeutic targets.
The group in the trial
- Patients operated for primary and recurrent glioblastoma
Patients operated for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux
Treatment: Relapsed glioblastoma
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Study of Metabolic, Genomic and Proteomic Modifications in Relapsed Glioblastoma. Identification or Prognostic Markers in Patients Undergoing Surgery for Relapsed Glioblastoma.
- Plain-language title
- Studies tumor changes in glioblastoma that has returned after treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 30 July 2025